Pulmonx posted a net loss of $10.1 million, or $0.24 per share, for the quarter ended June 30, narrowing the loss from $15.2 million a year earlier. The tighter loss and a record 78% gross margin suggest improving operating efficiency, which could bolster cash flow and support the company’s 2026 revenue targets.

Key Highlights

  • EPS beat consensus estimates while revenue fell 5% YoY to $22.8 million (U.S. sales $14.2 million; international $8.6 million)
  • Gross margin rose to 78% from 72% in the comparable period
  • Operating expenses dropped 16% to $26.8 million and Adjusted EBITDA loss shrank 39% to $5.1 million; cash and cash equivalents stand at $55.8 million

The results featured earnings per share that outperformed consensus estimates, alongside revenue of $22.8 million, a 5% decline year‑over‑year. U.S. sales contributed $14.2 million, while international sales amounted to $8.6 million.

The company recorded a gross margin of 78%, up from 72% in the comparable period, and reduced operating expenses by 16% to $26.8 million. Adjusted EBITDA loss decreased by 39% to $5.1 million, reflecting progress from ongoing cost‑realignment initiatives. The decline in expenses was driven by a restructuring of the sales organization and other efficiency measures.

Pulmonx ended the quarter with cash and cash equivalents of $55.8 million.

Why Now

The company’s margin expansion and expense reductions suggest that its cost‑optimization strategy is beginning to deliver results, even as top‑line growth remains modest. The narrowed loss and beat on earnings expectations provide a foundation for future performance, aligning with the firm’s guidance for 2026 revenue.

What to Watch Next

Stakeholders should follow the July 29, 2026 conference call transcript for additional insights into commercial execution and expense outlook. The upcoming third‑quarter earnings release will serve as a critical indicator of whether the margin improvements and cost controls can be sustained and translated into stronger cash generation.

Analysis based on the Form 8-K filed 29 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.